health
Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns
Xenon Pharmaceuticals on Thursday said it has temporarily paused enrolling new patients in clinical studies testing its experimental drug for major depression and bipolar disorder, following reports of mental and nervous system-related side effects.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Welsh hospital bans visitors amid outbreak of highly contagious Victorian disease
The Mirror
Winter flu vaccine rollout begins in Scotland
BBC
Doctor who touched student's hip and groin area cleared of sexual harassment
Cambridge News
Newborn baby fighting for life after being kissed by excited visitor as mum issues deadly warning
The Mirror
Mom And Daughter Asked To Never Be Told If The Other Passed Away, And Fate Granted Them That Wish
boredpanda.com